{
    "2019-11-18": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Shares",
                        "Up",
                        "Year to Date"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novo Nordisk downgraded by UBS on concerns over drug launch cost",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "downgraded",
                        "UBS",
                        "concerns",
                        "drug launch",
                        "cost"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}